Fig. 6: Treatment of tumor-bearing mice with lomitapide improves the therapeutic benefit of anti-PD-1 immunotherapy. | Cell Death & Disease

Fig. 6: Treatment of tumor-bearing mice with lomitapide improves the therapeutic benefit of anti-PD-1 immunotherapy.

From: Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR

Fig. 6

a Tumor growth curves of MC38 mouse colon cancer cells in mice treated with control (vehicle) or lomitapide combined with either control isotype or anti-PD-1. Lomitapide at 20 mg/kg every day, anti-PD-1 or isotype IgG 10 mg/kg every other day. Statistically significant differences (indicated by asterisks) are calculated using an unpaired two-tailed Student’s t-test (*P < 0.05, **P < 0.005, and ***P < 0.0005). b Representative images of tumor tissues at 18 days following inoculation of MC38 cells. c Representative results of immunofluorescence staining of CD8 (green), PD-L1 (red), and DAPI (blue) in MC38 tumor tissues. Scale bar: 20 μm.

Back to article page